IGC Pharma Inc (IGC)
0.447
+0.02
(+3.95%)
USD |
NYAM |
Apr 26, 16:00
0.48
+0.03
(+7.38%)
After-Hours: 20:00
IGC Pharma Research and Development Expense (Quarterly): 0.903M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.903M |
| September 30, 2023 | 1.268M |
| June 30, 2023 | 0.747M |
| March 31, 2023 | 0.493M |
| December 31, 2022 | 0.806M |
| September 30, 2022 | 0.768M |
| June 30, 2022 | 1.394M |
| March 31, 2022 | 1.233M |
| December 31, 2021 | 0.377M |
| September 30, 2021 | 0.276M |
| June 30, 2021 | 0.444M |
| March 31, 2021 | 0.334M |
| December 31, 2020 | 0.154M |
| Date | Value |
|---|---|
| September 30, 2020 | 0.219M |
| June 30, 2020 | 0.222M |
| March 31, 2020 | 0.247M |
| December 31, 2019 | 0.295M |
| September 30, 2019 | 0.222M |
| June 30, 2019 | 0.247M |
| March 31, 2019 | 0.811M |
| December 31, 2018 | 0.166M |
| September 30, 2018 | 0.278M |
| June 30, 2018 | 0.036M |
| March 31, 2018 | 0.079M |
| December 31, 2017 | 0.00 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.154M
Minimum
Dec 2020
1.394M
Maximum
Jun 2022
0.5605M
Average
0.377M
Median
Dec 2021
Research and Development Expense (Quarterly) Benchmarks
| CEL-SCI Corp | 4.352M |
| AIM ImmunoTech Inc | 3.20M |
| NovaBay Pharmaceuticals Inc | 0.004M |
| Protalix BioTherapeutics Inc | 3.102M |
| Palatin Technologies Inc | 5.554M |